Gastrointestinal perforation in metastatic carcinoma: a complication of bevacizumab therapy.
AffiliationDepartment of Surgery, St Vincent's University Hospital, Elm Park, Dublin 4,, Dublin, Ireland. firstname.lastname@example.org
MeSHAbdominal Pain/drug therapy/etiology
Angiogenesis Inhibitors/*adverse effects
Anti-Inflammatory Agents, Non-Steroidal/therapeutic use
Antibodies, Monoclonal/*adverse effects
Antibodies, Monoclonal, Humanized
Confounding Factors (Epidemiology)
Intestinal Perforation/*chemically induced
Wound Healing/drug effects
MetadataShow full item record
CitationEur J Surg Oncol. 2009 Apr;35(4):444-6. Epub 2008 Apr 15.
JournalEuropean journal of surgical oncology : the journal of the European Society of, Surgical Oncology and the British Association of Surgical Oncology
- [Surgical management of bevacizumab-associated peritonitis due to perforation].
- Authors: Kube R, Meyer F, Bien N, Schmidt C, Mroczkowski P, Dalicho S, Lippert H
- Issue date: 2009 Sep
- Endoscopic management of colonic perforation owing to angiogenesis inhibitors.
- Authors: Ezzedine S, Bege T, Berdah S, Vitton V, Grimaud JC, Barthet M
- Issue date: 2010 Dec
- Bowel perforation from bevacizumab for the treatment of metastatic colon cancer: incidence, etiology, and management.
- Authors: Heinzerling JH, Huerta S
- Issue date: 2006 Sep-Oct
- What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer?
- Authors: Han ES, Monk BJ
- Issue date: 2007 Apr
- Gastrointestinal ulceration as a possible side effect of bevacizumab which may herald perforation.
- Authors: Tol J, Cats A, Mol L, Koopman M, Bos MM, van der Hoeven JJ, Antonini NF, van Krieken JH, Punt CJ
- Issue date: 2008 Aug